ICMR & CDSCO Invite Stakeholder Comments on Draft Standard IVD Evaluation Protocol

In the realm of healthcare, accurate diagnostics are the cornerstone of effective treatment and disease management. Recognizing the critical need for reliable diagnostic tools, the Indian Council of Medical Research (ICMR) and the Central Drugs Standard Control Organization (CDSCO) have joined forces to establish standardized protocols for evaluating the performance of In-Vitro Diagnostic (IVD) kits. These protocols, developed under the Medical Devices Rules 2017, aim to ensure the quality, sensitivity, and specificity of diagnostic kits used in India.

Why Standardized Protocols Matter

The COVID-19 pandemic underscored the importance of robust diagnostic systems. With the rapid development of diagnostic kits for SARS-CoV-2, the need for standardized evaluation became evident. ICMR and CDSCO’s protocols provide a systematic framework for assessing diagnostic kits, ensuring they meet international standards and are suitable for the Indian healthcare landscape.

Scope of the Protocols

The protocols cover a wide range of diagnostic kits, including those for respiratory viruses like Influenza, SARS-CoV-2, and Respiratory Syncytial Virus (RSV), as well as kits for vector-borne diseases like Malaria and Dengue. They also extend to emerging pathogens like Nipah and Chandipura viruses, and multiplex assays for respiratory viruses.

Key Features of the Protocols

Comprehensive Evaluation: The protocols assess various performance characteristics, including sensitivity, specificity, cross-reactivity, repeatability, and reproducibility.
Standardized Sample Panels: Statistically significant sample sizes are used to ensure rigorous testing. Positive and negative samples are carefully characterized using reference assays.
Blinded Testing: To eliminate bias, laboratory staff conducting evaluations are blinded to the status of clinical samples.
Ethical Compliance: The use of irreversibly de-identified samples ensures ethical compliance, exempting the process from requiring ethics approval.
Publication Rights: Evaluating labs retain the rights to publish findings, promoting transparency and scientific collaboration.

Protocols for Specific Diseases

Respiratory Viruses

Protocols for Influenza, SARS-CoV-2, and RSV focus on molecular diagnostic kits using single-plex or multiplex formats. These kits are evaluated for their ability to detect and differentiate between virus types and subtypes.

Malaria

Malaria diagnostic kits, including Rapid Diagnostic Tests (RDTs), ELISA, and PCR assays, are evaluated for their ability to detect Plasmodium species with varying parasitemia levels. The protocols emphasize the importance of using well-characterized sample panels.

Dengue

Protocols for Dengue diagnostics include IgG RDT kits, IgM/IgG combo kits, and ELISA assays. These kits are assessed for their ability to diagnose primary and secondary infections and differentiate between flavivirus antibodies.

Emerging Pathogens

For Nipah and Chandipura viruses, the protocols require specialized facilities like BSL-4 labs and focus on RNA extraction and real-time PCR systems. These protocols are crucial for handling zoonotic diseases with high public health impact.

Multiplex Assays

Multiplex assays for respiratory viruses are evaluated for their ability to detect multiple pathogens simultaneously. The protocols ensure that these kits meet high standards of sensitivity and specificity.

Stakeholder Involvement

The draft protocols are open for stakeholder comments until August 25, 2025. This collaborative approach ensures that the protocols are comprehensive and address the needs of manufacturers, healthcare providers, and regulatory bodies.

Conclusion

ICMR and CDSCO’s standardized protocols represent a significant step forward in ensuring the quality and reliability of diagnostic kits in India. By setting rigorous evaluation standards, these protocols not only enhance public health but also foster innovation in the diagnostic industry. As stakeholders contribute their insights, these protocols will continue to evolve, ensuring that India remains at the forefront of diagnostic excellence.

In case you face any issues related to Indirect Tax-Customs, GST, Foreign Trade Policy (FTP), Arbitration matters and Central Licensing and related advisory matters in India then please feel free to get in touch with SJ EXIM Services.

We offer Legal advice and litigation support in matters related to Indirect Tax-Customs, FTP, other Indirect Tax matters & Arbitration law, all sorts of Central licensing and related matters. Come and explore the new way of doing business with us!

Source: CDSCO

Disclaimer

Handy Download:

CDSCO Public NoticeDownload

Connect with us for more-

@ Team S J EXIM SERVICES, New Delhi, IN

CP: Ms. Shubhra Jha, Founder

Tel: +91-11-4999 2707 I +91-9999005693

Web: www.sjexim.services

EMAIL: operations@sjexim.services I shubhra@sjexim.services

Facebook: www.facebook.com/sjeximservices

LinkedIn: https://www.linkedin.com/company/90794255/admin/feed/posts/

YouTube: https://www.youtube.com/@sjeximIndia

Subscribe our WhatsApp Channel: https://whatsapp.com/channel/0029VaTxDT8JZg4CHEOSoK47

Subscribe our Telegram Channel: https://t.me/sjeximindia

S J EXIM Services